Entering text into the input field will update the search result below

Xenon Pharmaceuticals' (XENE) CEO Simon Pimstone on Q4 2017 Results - Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

Xenon Pharmaceuticals, Inc. (NASDAQ:XENE) Q4 2017 Results Earnings Conference Call March 7, 2018 4:30 PM ET


Jodi Regts - Senior Director, Corporate Affairs

Simon Pimstone - President and CEO

Ian Mortimer - CFO and COO


Maury Raycroft - Jefferies

Philomena Kamya - Stifel


Good day, ladies and gentlemen, and welcome to the Xenon Pharmaceuticals' Fiscal Year 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. [Operator Instructions] As a reminder, this conference call is being recorded.

I would now like to turn the conference over to Ms. Jodi Regts. Ms. Regts you may begin.

Jodi Regts

Thank you. Good afternoon. Thank you for joining us on our call and webcast to discuss our financial and operating results for the year ended December 31st, 2017. Joining me on today's call are Dr. Simon Pimstone, Xenon's President and Chief Executive Officer; and Ian Mortimer, Xenon's Chief Financial Officer and Chief Operating Officer. Following this introduction, Simon will provide perspective on Xenon's progress and then Ian, will review our financial results. After that, we will open up the call to your questions.

Please be advised that during this call, we will make a number of statements that are forward-looking, including statements about the sufficiency of our capital position to execute on our business objectives and our ability to operate in a capital efficient manner; our expectations regarding the sufficiency of our cash to fund operations into mid-2019, the timing of IND or IND equivalent submissions with regulatory agencies; the initiation of future clinical trials, the potential efficacy, future development plans and commercial potential of our and our collaborators product candidate, the timing as and results from ongoing clinical trials and pre-clinical development activities, our ability to achieve certain milestones

Recommended For You

Comments (4)

sbrncra profile picture
No news on this version of nav might mean trying alternative tweaking. XENE already reported topical version so looks like possibly Genentech is doing a better look at potential of tweak??
sbrncra profile picture
Should be news very soon
sbrncra profile picture
XENE also still with Genentech on a pain med development?
sbrncra profile picture
“which may allow us to advance this product candidate either on our own or in partnership directly into a Phase 2 clinical trial which we believe could start in 2018”
To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!

About XENE

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on XENE

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.